Core Insights - DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals, valued at approximately $3.89 million, as reported in an SEC filing dated February 17, 2026 [1][2] - The value of Syndax's stake at the end of the fourth quarter decreased by $1.87 million due to share sales and price movements [2] Company Overview - Syndax Pharmaceuticals is a biotechnology company focused on developing novel cancer therapies, particularly for hematologic malignancies and immune-mediated conditions [5] - The company has a market capitalization of $2.1 billion and reported revenue of $172.4 million for the trailing twelve months (TTM) [4] - Syndax's net income for the TTM is reported at a loss of $285.4 million [4] Financial Performance - As of the latest report, Syndax shares are priced at $24.23, reflecting a 72% increase over the past year, significantly outperforming the S&P 500, which rose about 15% in the same period [7] - The fund's position in Syndax now represents 1.36% of its $430.52 million reportable assets, down from 1.90% in the previous quarter [7] Product Pipeline and Market Position - Syndax is advancing its pipeline with products like SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease, alongside other therapies [8] - The company is transitioning from a clinical-stage to a commercial-stage biotech, generating real revenue and showing strong momentum from two commercial products [9] - This transition is significant but comes with increased operating costs and substantial ongoing losses [9] Strategic Insights - The recent share sale by DAFNA Capital Management indicates a disciplined approach to managing exposure within a biotech-heavy portfolio, especially after a significant stock price increase [6] - Syndax's ability to build a credible commercial base while advancing its pipeline positions it as a key innovator in the biopharmaceutical sector, though it may also lead to volatility as market expectations adjust [10]

Company Overview - Syndax Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel cancer therapies, leveraging a targeted pipeline strategy for high-need oncology indications supported by strategic collaborations and licensing agreements [5][6] - As of the latest data, the company's stock price is $24.23, with a market capitalization of $2.1 billion and total revenue of $172.4 million over the trailing twelve months (TTM) [4][5] - The company reported a net income loss of $285.4 million (TTM), indicating ongoing cash burn due to high operating expenses related to research and development (R&D) and commercialization [4][9] Recent Transactions - Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, during the fourth quarter of 2025, reducing its position to 10.81% of reportable 13F assets under management [2][5] - Following the sale, the value of Kynam's Syndax position increased by $38.07 million, reflecting both trading and share price movements [2] Performance Metrics - Syndax's stock has surged over 72% in the past year, significantly outperforming the S&P 500's approximate 15% gain during the same period [5] - The company generated about $172 million in total revenue last year, with approximately $124.8 million coming from its recently launched therapies, including Revuforj, and additional contributions from its Niktimvo collaboration [8] Investment Implications - The transaction by Kynam Capital Management suggests a strategic adjustment rather than a complete exit, as the remaining stake still represents a significant portion of their assets [10] - The ongoing tension between growth and profitability is evident, as the company continues to invest heavily in R&D while facing substantial net losses [9]

Summary of Syndax Pharmaceuticals FY Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Focus**: Oncology with two leading products targeting acute leukemia and chronic graft-versus-host disease (GVHD) [2][4] Key Products 1. **Revuforj**: - Targets KMT2A and NPM1 acute leukemia, covering approximately 50% of the acute leukemia market [2] - Launched in late 2024, with significant sales growth, achieving $152 million in sales in 2025 [3][4] - Expected to become the standard of care for NPM1 and relapsed refractory disease [6] - Anticipated average duration of therapy to increase from 4-6 months in 2025 to 6-12 months in 2026 due to maintenance therapy [10][11] 2. **Niktimvo**: - A CSF1R inhibitor for chronic GVHD, launched in early 2025 [3] - Achieved $152 million in sales within its first year [4] Market Position and Strategy - Syndax is positioned as a leader in the menin inhibitor class, with a broad label covering various indications [12] - The company emphasizes early treatment to improve patient outcomes, particularly in younger patients who can benefit from transplants [6][7] - Strong commercial and medical organization to support physician engagement and data dissemination [12][14] Financial Management - Operating expenses are maintained at $400 million for SG&A plus R&D, allowing for investment in both commercial and pipeline activities [19][20] - Successful product launches are contributing to gross margins that offset operational costs [20] Combination Therapy Insights - Revuforj is being used increasingly in combination therapies, with reported response rates of 70-80% compared to 50% for monotherapy [25] - The drug is well-tolerated in combination settings, with no significant incremental toxicity [26][27] - Physicians are encouraged to use Revuforj in combination due to its efficacy and safety profile [29] Clinical Trials and Future Directions - Ongoing studies focus on safety and efficacy in combination therapies, with endpoints including complete response rates and event-free survival [32][34] - The company is exploring the use of Revuforj in earlier treatment lines and in combination with other therapies [30][31] - Plans to announce clinical trial programs for myelofibrosis, leveraging promising preclinical data [40][41] Axatilimab Development - Axatilimab is showing promise in treating GVHD, with ongoing trials to assess its efficacy in combination with standard therapies [44][47] - The drug is expected to move into earlier lines of therapy based on positive data from ongoing studies [48][50] IPF Development - A phase 2 study (MAXRR) is underway, with plans for a phase 3 study contingent on favorable results [53][54] - The company is developing a subcutaneous formulation for potential use in phase 3 trials [54][55] Conclusion - Syndax Pharmaceuticals is strategically positioned in the oncology market with innovative therapies and a strong focus on combination treatments and early intervention strategies. The company is committed to maintaining operational efficiency while investing in future growth opportunities through clinical trials and product development.

Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [33] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [33] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [18][33] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax [8][9] Market Data and Key Metrics Changes - The KMT2A business showed continued growth as the number of patients on therapy post-transplant began to increase significantly [7] - The NPM1 market opportunity is estimated to triple the annual addressable patient population to 6,500 patients, with early data indicating strong uptake [13][15] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, with Revuforj positioned as the leading menin inhibitor in both relapsed refractory and frontline settings [36] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock significant market opportunities [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and clinical data [9][11] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [35] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [10][28] - The company anticipates stable expenses in 2026, guiding total R&D plus SG&A expenses to approximately $400 million [35] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A has been significant, with a third of patients going to transplant and an increasing number returning for maintenance therapy, which is expected to continue growing [40][41] Question: What is the expected steady state for NPM1 patient starts? - Management indicated that they expect the percentage of NPM1 patient starts to grow significantly, potentially reaching a 50/50 split with KMT2A patients as awareness and access improve [43][45] Question: What are the criteria for determining the go-forward decision on the IPF indication? - Management highlighted the importance of statistical significance and clinical relevance against historical controls, with a focus on achieving a meaningful difference in forced vital capacity [47][49] Question: How quickly can a pivotal trial for IPF be initiated if the phase II trial reads out positively? - Management expressed intent to design and execute the next trial as quickly as possible, with plans for a phase III trial based on the positive results from the phase II study [52][53] Question: Are physicians comfortable with the dosing of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming more comfortable with the dosing as maintenance use increases, supported by ongoing studies to optimize dosing [61][62] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - Management explained that they are pursuing innovative approaches, including trials with venetoclax, to potentially reduce morbidity while achieving similar outcomes to intensive chemotherapy [66][67]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [35] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [35] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [19][35] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax in 2025 [8][19] Market Data and Key Metrics Changes - The KMT2A patient population is approaching 50% penetration within the first year of Revuforj's launch, with approximately 1,050 patients treated commercially [12] - NPM1 patients represented about 30% of new patient starts, with expectations for this number to grow significantly [46][47] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, targeting a total addressable market opportunity exceeding $10 billion [9] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock new market opportunities [10][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and market access [7][9] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [37] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [30] - The company is positioned to deliver impactful real-world evidence supporting revumenib's clinical use [29] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A maintenance therapy is driven by a significant number of patients returning for maintenance after transplant, with expectations for continued growth [43] Question: What is the expected steady-state percentage of NPM1 patient starts? - Management anticipates that the percentage of NPM1 patient starts will grow meaningfully throughout the year, with current estimates around 30% [46][47] Question: What are the benchmarks for the IPF trial to determine the go-forward decision? - The primary endpoint is the annualized rate of decline in forced vital capacity, with expectations for a statistically significant and clinically meaningful difference compared to historical controls [49][50] Question: What is the fastest path to a pivotal trial for IPF if the data reads out positively? - Management indicated that they would be as expeditious as possible in designing the next trial, with plans for a phase 3 trial following a positive phase 2 outcome [54][55] Question: Are physicians comfortable with the dose of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming increasingly comfortable with the dosing for maintenance therapy, supported by ongoing studies [64] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - The strategy includes a randomized study planned in collaboration with the NCI, focusing on innovative approaches to reduce morbidity while maintaining efficacy [68][69]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [34] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [34] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [18] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [4][5] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax in 2025 [6][34] Market Data and Key Metrics Changes - The KMT2A business is experiencing growth as the number of patients on therapy post-transplant increases, with approximately one-third of KMT2A patients treated with Revuforj proceeding to stem cell transplant [15] - The NPM1 market opportunity is expanding, with the addressable patient population tripling to 6,500 patients following the label expansion for Revuforj [12] Company Strategy and Development Direction - The company aims to continue investing in strategic priorities to fuel growth, including advancing life cycle and frontline programs to unlock over $10 billion in total addressable market opportunity [8] - Syndax is focused on establishing Revuforj as the menin inhibitor of choice in the relapsed refractory setting and the first menin inhibitor approved in the frontline, targeting a $5 billion-plus market opportunity [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of both Revuforj and Niktimvo, supported by multiple growth drivers and a well-funded position to invest in commercial and development priorities [8][34] - The company anticipates that the average treatment duration for Revuforj will extend from 4-6 months in the first year to 6-12 months in the second year as treatment patterns mature [17] Other Important Information - The company completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [29] - Syndax is well-funded with $394 million in cash, equivalents, and marketable securities at the end of 2025, expecting to reach profitability without the need for additional capital [37] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A has been significant, with a rising number of patients returning for maintenance therapy post-transplant, increasing from 35%-40% to 40%-45% [42][43] Question: What is the expected steady-state percentage for NPM1 patient starts? - Management expects the percentage of NPM1 patient starts to grow significantly, potentially reaching a 50/50 split with KMT2A patients as awareness and access improve [45][48] Question: What are the criteria for determining the go-forward decision on the IPF indication? - The primary endpoint for the IPF study is the annualized rate of decline in forced vital capacity, with management looking for statistically significant and clinically meaningful results compared to historical controls [50][51] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - Management is pursuing an innovative approach with the RAVEN trial, aiming to combine Revuforj with venetoclax to potentially reduce morbidity while achieving similar outcomes to intensive chemotherapy [64][70]

Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements ...

Summary of Syndax Pharmaceuticals Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Date**: February 12, 2026 - **Key Speakers**: Michael Metzger (CEO), Nick Botwood (CMO, Head of R&D), Keith Goldan (CFO) Core Points and Arguments Financial Performance - **Revuforj**: Achieved $125 million in annual net sales, with a quarter-over-quarter growth of 38% in Q4 2025, indicating strong market performance and expansion in its labeled indications [2][4] - **Niktimvo**: Generated $152 million in sales within the first 11 months of launch for chronic GVHD, also showing significant quarter-over-quarter growth [2] Product Development and Market Strategy - **Revuforj**: - Focused on KMT2A and NPM1 indications, with new NCCN guidelines and approvals driving growth [4][5] - Anticipated to capture a dominant market share in NPM1, similar to its established position in KMT2A [9] - Current maintenance therapy uptake for KMT2A is 35%-40%, with expectations to grow to 70%-80% over time [10][13] - **Niktimvo**: - Currently approved for later-line chronic GVHD, with a potential market of approximately 6,500 patients in the U.S. for third-line treatment, and an estimated peak opportunity approaching $1 billion [23][24] - Collaboration with Incyte involves a 50/50 profit split, with expectations for long-term growth in revenue share [24][26] Research and Development - **IPF Phase II Trial**: - Expected to read out in the second half of 2026, with a well-designed study focusing on forced vital capacity as the primary endpoint [30][34] - Strong preclinical data supports the role of CSF1R inhibition in IPF, with significant improvements noted in related conditions [32][40] - **Future Opportunities**: - Plans to explore the role of revumenib in myeloproliferative neoplasms (MPN), with promising preclinical results [20][21][22] Path to Profitability - Syndax aims for profitability potentially by 2027, supported by strong revenue from both Revuforj and Niktimvo, while maintaining flat operating expenses at $400 million [46] Additional Important Insights - The company is fully funded and does not require additional cash, positioning it well for future growth [46] - The collaboration with Incyte extends to future trials, including potential IPF studies, with shared costs and responsibilities [45] This summary encapsulates the key points discussed during the conference call, highlighting the financial performance, product development strategies, research initiatives, and the company's path to profitability.

Syndax Pharmaceuticals Update Summary Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS: SNDX) - **Focus**: Development and commercialization of innovative therapies for cancer, specifically targeting chronic graft-versus-host disease (GVHD) and acute leukemia Key Products - **Niktimvo**: - Indicated for chronic GVHD in the third line and beyond - Total addressable market of approximately $2 billion in the U.S. - Achieved $96 million in net sales since launch, with annualized sales projected at $200 million within the first eight months - First and only CSF1R blocking antibody approved for chronic GVHD - 80% of patients who started treatment have remained on it - **Revuforj**: - First menin inhibitor approved for multiple acute leukemia subtypes - Total addressable market exceeding $5 billion - Generated $88 million in net revenue as of Q3, with a 25% growth in total prescriptions and new patient starts over 2020 - 50% penetration of the 2,000 incidence market for KMT2A patients expected by year-end Clinical Developments - **Clinical Trials**: - Extensive development programs for both Niktimvo and Revuforj, with ongoing trials aimed at expanding indications and improving treatment paradigms - Trials underway for Niktimvo in combination with Jakafi and steroids to address chronic GVHD in frontline settings - Revuforj positioned for long-term growth with ongoing trials in newly diagnosed patients - **Data Presentations**: - 23 presentations at ASH, including three oral presentations for Revuforj and nine poster presentations - Highlighted the breadth of data supporting both products, showcasing efficacy and safety profiles Market Position and Strategy - **Market Opportunity**: - Syndax is targeting a combined total addressable market of $10 billion with its two key products - The company aims to build multi-billion-dollar franchises with both Niktimvo and Revuforj - **Commercial Strategy**: - Engaged extensively with healthcare professionals (HCPs) through over 100 meetings and educational opportunities - Positive feedback on product profiles and commercial presence at industry events Financial Outlook - **Revenue Growth**: - Both products are expected to contribute significantly to revenue, with a path to profitability anticipated in the coming years - Stable expense guidance provided, indicating a sustainable growth engine Additional Insights - **Patient Treatment Dynamics**: - High percentage of patients transitioning to post-transplant maintenance treatment, indicating strong physician interest in long-term management strategies - Emphasis on the importance of maintaining treatment duration and dose intensity for chronic GVHD patients - **Safety and Efficacy**: - Long-term safety data supports the use of axatilimab (Niktimvo) for extended periods, with no new safety concerns identified - Ongoing studies aim to explore the potential of moving effective agents into frontline therapy to improve patient outcomes - **Future Directions**: - Continued focus on expanding indications and improving treatment protocols for chronic GVHD and acute leukemia - Anticipation of further data releases and updates on clinical trials to inform treatment strategies and market positioning This summary encapsulates the key points from the Syndax Pharmaceuticals update, highlighting the company's strategic focus, product performance, clinical developments, and market outlook.

Financial Data and Key Metrics Changes - The company expects to transition its business model post-Jakafi, aiming for a five-year compound annual growth rate (CAGR) of 15%-20% with multiple products projected to generate over $1 billion in revenue each [6][20][21] - Jakafi sales are anticipated to be preserved with the launch of a once-daily formulation, potentially maintaining nearly $750 million in sales through 2029 [7][8] Business Line Data and Key Metrics Changes - The core business, excluding Jakafi, is projected to grow significantly, potentially matching Jakafi's revenue by 2029 [4][6] - Opzelura finished the year with approximately $650 million in sales, with expectations of a 10% CAGR, potentially doubling by 2030 [21][22] - The company has seven late-stage pipeline projects that could enhance its core business in hematology, oncology, and immunology [4][6] Market Data and Key Metrics Changes - The U.S. market is experiencing a shift from topical corticosteroids to nonsteroidal topicals, with Opzelura positioned to benefit from this trend [21][22] - The company anticipates approval for Opzelura in moderate atopic dermatitis in Europe by mid to late 2026, which could significantly drive growth [23][24] Company Strategy and Development Direction - The company aims to establish a targeted therapy for every patient with myeloproliferative neoplasms (MPNs) by the end of the decade, with a focus on executing clinical trials efficiently [18][19] - Business development efforts will focus on extending the core in hematology, oncology, and immunology [4][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline's potential, emphasizing the importance of execution and the favorable positioning of their products in competitive markets [6][20] - The company is aware of competition but believes it has a strong lead in several therapeutic areas, particularly with its G12D inhibitor and other oncology programs [20][55] Other Important Information - The company is preparing for the submission of povorcitinib in the U.S. in early 2026, with expectations of a launch by late 2026 or early 2027 [31][32] - The company has a robust consumer campaign for vitiligo treatment, aiming to increase diagnosis and treatment rates [26] Q&A Session Summary Question: Can you discuss the growth potential of Opzelura? - Opzelura is expected to grow at a 10% CAGR, potentially reaching $1.3 billion by 2030, driven by increased market penetration and new indications [21][22] Question: What is the timeline for the submission of povorcitinib? - The submission for povorcitinib is planned for early 2026, with potential approval by late 2026 or early 2027 [31][32] Question: How does the company view its competitive positioning in the market? - The company believes it has a strong lead in the market, particularly with its G12D inhibitor, and is focused on executing its clinical trials effectively [20][55] Question: What are the expectations for the upcoming data presentations? - The company is preparing to present data at ASH, which will provide further insights into its pipeline and product efficacy [62]